CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast cancer. One randomized clinical trial (CREATE...

Descripción completa

Detalles Bibliográficos
Autores principales: Zujewski, Jo Anne, Rubinstein, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519731/
https://www.ncbi.nlm.nih.gov/pubmed/28758147
http://dx.doi.org/10.1038/s41523-017-0029-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519731/
https://www.ncbi.nlm.nih.gov/pubmed/28758147
http://dx.doi.org/10.1038/s41523-017-0029-3

Ejemplares similares